VOLUME 10 (2019)
View Archive »
About The Cover
The cover for issue 19 of Oncotarget features Figure 4, "Gene network analysis using IPA program," by Li, et al.
|
|
Table of Contents
Editorial
|
| Targeting the bone marrow microenvironment: a novel therapeutic strategy for preB acute lymphoblastic leukemia |
|
https://doi.org/10.18632/oncotarget.26720
|
| 1756-1757 |
|
| The molecular landscape of adult diffuse gliomas and relevance to clinical trials |
|
https://doi.org/10.18632/oncotarget.26750
|
| 1758-1759 |
Priority Research Papers
|
| Genetic interaction analysis among oncogenesisrelated genes revealed novel genes and networks in lung cancer development |
|
https://doi.org/10.18632/oncotarget.26678
|
| 1760-1774 |
Research Papers
|
| Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.26633
|
| 1775-1784 |
|
| DICER1 somatic mutations strongly impair miRNA processing even in benign thyroid lesions |
|
https://doi.org/10.18632/oncotarget.26639
|
| 1785-1797 |
|
| Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition |
|
https://doi.org/10.18632/oncotarget.26734
|
| 1798-1811 |
|
| Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cellbased vaccines |
|
https://doi.org/10.18632/oncotarget.26737
|
| 1812-1828 |
|
| Implication of integrin α2β1 in anoikis of SKMel147 human melanoma cells: a noncanonical function of Akt protein kinase |
|
https://doi.org/10.18632/oncotarget.26746
|
| 1829-1839 |
|
| An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.26748
|
| 1840-1849 |
|
| Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib MEK162 in patients with advanced NRAS or BRAFmutated melanoma |
|
https://doi.org/10.18632/oncotarget.26753
|
| 1850-1859 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß